Product Information
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Major Pharmaceuticals, priced at $0.6881 per EA under NDC 00904662461. Its NADAC has been published 484 times since Apr 26, 2017.
FDA first approved this application on May 12, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904662461
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TACROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA090509FDA Approved
5/12/2010
TE Code
AB
On Market Since
5/14/2010
Pharmacological Classes
Price Statistics
The NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has been published 484 times since Apr 26, 2017, and over the history we have for it it has declined 78.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6881 per EA |
|---|---|
| All-time high | $4.3509 (Sep 16, 2020) |
| All-time low | $0.6505 (Jun 17, 2026) |
| 52-week high | $0.8265 |
| 52-week low | $0.6505 |
| Median price | $1.5754 |
| Average price | $1.7552 |
| Largest weekly change | +172.0% (Dec 13, 2017) |
| Weeks tracked | 484 |
| Tracking since | Apr 26, 2017 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tacrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Major Pharmaceuticals, is $0.6881 per EA (NDC 00904662461), effective Sep 30, 2026.
How has the price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?
Over the history we have for it, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has declined 78.9%. It has been tracked across 484 weekly CMS publications since Apr 26, 2017.
What are the highest and lowest recorded NADAC prices for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Since Apr 26, 2017, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.6505 (Jun 17, 2026) to a high of $4.3509 (Sep 16, 2020), with a median of $1.5754 per EA.
Are there cheaper alternatives to TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), is $0.6746 per EA — about 2% below TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE).
Who manufactures TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?
TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 00904662461) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.